At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 186 enrolled
Drug / intervention
GSK2402968 6mg/kg/weekdrug
Likely dose
GSK2402968 6mg/kg/weekfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Randomized, Double Blind, Placebo-controlled Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular Dystrophy
In Brief
A Phase 3 clinical trial evaluating GSK2402968 6mg/kg/week for Muscular Dystrophies. Completed, enrolled 186 participants across 47 sites in 20 countries.
Detailed Summary
The purpose of this study is to determine whether GSK2402968 is effective in the treatment of ambulant boys with Duchenne muscular dystrophy resulting from a mutation thought to be corrected by exon 51 skipping.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMuscular Dystrophies
CountriesArgentina, Belgium, Brazil, Canada, Chile, Czechia, Denmark, France, Germany, Hungary, Italy, Japan, Netherlands, Norway, Poland, Russia, South Korea, Spain, Taiwan, Turkey (Türkiye)
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2010
First PostedDec 2010
Primary CompletionJun 2013
TodayJul 2026
First PostedDec 6, 2010
Enrollment StartDec 2, 2010
Primary CompletionJun 28, 2013
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 15.6 years ago
Interventions
GSK2402968 6mg/kg/weekdrug
subcutaneous